5 reports of this reaction
3.5% of all CAMPHOR, MENTHOL, METHYL SALICYLATE reports
#2 most reported adverse reaction
APPLICATION SITE BURN is the #2 most commonly reported adverse reaction for CAMPHOR, MENTHOL, METHYL SALICYLATE, manufactured by Hisamitsu America, Inc.. There are 5 FDA adverse event reports linking CAMPHOR, MENTHOL, METHYL SALICYLATE to APPLICATION SITE BURN. This represents approximately 3.5% of all 141 adverse event reports for this drug.
Patients taking CAMPHOR, MENTHOL, METHYL SALICYLATE who experience application site burn should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
APPLICATION SITE BURN is moderately reported among CAMPHOR, MENTHOL, METHYL SALICYLATE users, representing a notable but not dominant share of adverse events.
In addition to application site burn, the following adverse reactions have been reported for CAMPHOR, MENTHOL, METHYL SALICYLATE:
The following drugs have also been linked to application site burn in FDA adverse event reports:
APPLICATION SITE BURN has been reported as an adverse event in 5 FDA reports for CAMPHOR, MENTHOL, METHYL SALICYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
APPLICATION SITE BURN accounts for approximately 3.5% of all adverse event reports for CAMPHOR, MENTHOL, METHYL SALICYLATE, making it one of the most commonly reported side effect.
If you experience application site burn while taking CAMPHOR, MENTHOL, METHYL SALICYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.